Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alnylam PharmaceuticalsLTS:0HD2 +2.23%65 Equity-to-Asset is 0.24 as of Jun. 2026, which is at its 10-year median of 0.24. GuruFocus rates LTS:0HD2 with a GF Score™ of 65/100 and a GF Value™ of $523.13 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 1,414 Biotechnology companies, Alnylam Pharmaceuticals ranks worse than 80.76% on this metric.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Alnylam Pharmaceuticals Equity-to-Asset Related Terms
Alnylam Pharmaceuticals Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0HD2 vs RPRX, INSM, BNTX: Equity-to-Asset Comparison
For the Biotechnology subindustry, Alnylam Pharmaceuticals's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alnylam Pharmaceuticals Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alnylam Pharmaceuticals's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Alnylam Pharmaceuticals's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Alnylam Pharmaceuticals's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alnylam Pharmaceuticals (LTS:0HD2) has a Equity-to-Asset of 0.24 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Alnylam Pharmaceuticals and its competitors. This is near median its historical median of 0.24. According to the industry distribution chart, Alnylam Pharmaceuticals ranks #1142 out of 1414 companies in the Biotechnology industry, placing it in the top 80.8%.
Is Alnylam Pharmaceuticals' Equity-to-Asset too high?
Alnylam Pharmaceuticals' current Equity-to-Asset of 0.24 is near median its 10-year median of 0.24. The Biotechnology industry median Equity-to-Asset is 0.68. Alnylam Pharmaceuticals' value of 0.24 is 64.7% below this industry median. Based on the distribution chart, Alnylam Pharmaceuticals ranks #1142 out of 1414 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Alnylam Pharmaceuticals has a GF Score™ of 65/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alnylam Pharmaceuticals' Equity-to-Asset compare to RPRX and INSM?
According to the Biotechnology industry distribution chart, Alnylam Pharmaceuticals ranks #1142 out of 1414 companies for Equity-to-Asset. This places Alnylam Pharmaceuticals in the lower half of its industry. The industry median Equity-to-Asset is 0.68. Alnylam Pharmaceuticals' value of 0.24 is 64.7% below this benchmark. While the company's 10-year median is 0.24 vs. the industry median of 0.68, Alnylam Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,414 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alnylam Pharmaceuticals's current Equity-to-Asset of 0.24 is 64.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Alnylam Pharmaceuticals and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alnylam Pharmaceuticals's current Equity-to-Asset is 0.24, which is near median its own 10-year median of 0.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alnylam Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Alnylam Pharmaceuticals (LTS:0HD2) is currently considered Significantly Undervalued. The stock's GF Value™ is $523.13, compared to a current price of $241.19 — trading 53.9% below its estimated fair value. The current Equity-to-Asset is 0.24, which is near median its 10-year median of 0.24 and 64.7% below the Biotechnology industry median of 0.68. Alnylam Pharmaceuticals' overall GF Score™ is 65/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Alnylam Pharmaceuticals (LTS:0HD2), the current Equity-to-Asset is 0.24 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alnylam Pharmaceuticals (LTS:0HD2) Overvalued in 2026?
Based on GuruFocus' analysis, Alnylam Pharmaceuticals stock appears to be undervalued.
The current stock price of $241.19 is trading 53.9% below its estimated GF Value™ of $523.13.
GuruFocus considers Alnylam Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for LTS:0HD2:
Equity-to-Asset: 0.24 (near median its 10-year median of 0.24)
GF Value™: $523.13 vs. price of $241.19 (53.9% below fair value)
Industry Position: 64.7% below the Biotechnology median (#1142 of 1414)
No single metric tells the full story. See the LTS:0HD2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
65GF Score
Get the complete analysis for LTS:0HD2
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0HD2 has been successfully added to your 
